Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01912040

Enrollment

Registered

2013-07-30

Start date

2006-07-31

Completion date

2018-12-31

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenergic Pathology

Keywords

Safety profile, locally produced 123 Iodine MIBG

Brief summary

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Detailed description

We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.

Interventions

DRUGAdministration of 123Iodine MIBG

Patients will be administered the locally produced 123 Iodine MIBG

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Months to No maximum

Healthy volunteers

Inclusion criteria

* Patients with potential Adrenergic pathology

Exclusion criteria

* Pregnant or breast feeding females * Hypersensitivity to MIBG

Design outcomes

Primary

Measure	Time frame
Safety profile of the 123Iodine MIBG	BP and Heart rate for 24 hours after injection.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026